

SCANNED, # 12






Figure 1



[illegible]

Figure 3A

B

placebo



A

LJP 394




Figure 4A & 4B




Figure 4C & 4D

Figure 5A & 5B






Figure 7




Figure 8



[illegible]

* Data excluded after HDCC

Figure 10




* analysis includes 69 of 114 patients treated with LJP 394
 analysis includes 14 of 19 lupus flares from drug treated group

Figure 11A


Figure 11B & 11C

- LJP 394 flares
- placebo flares




* data represents 15 of 19 LJP 394 flares and 14 of 23 placebo flares

Figure 12



* analysis includes 36 of 115 patients treated with placebo
graph identifies 14 of 23 lupus flares from placebo treated group

Figure 13



* HDCC = First incidence of high dose corticosteroids +/- cyclophosphamide

Figure 15

